Article thumbnail

Association of Skin with the Pathogenesis and Treatment of Neurodegenerative Amyloidosis

By Audra L. Clos, Rakez Kayed and Cristian A. Lasagna-Reeves

Abstract

Amyloidosis are a large group of conformational diseases characterized by abnormal protein folding and assembly which results in the accumulation of insoluble protein aggregates that may accumulate systemically or locally in certain organs or tissue. In local amyloidosis, amyloid deposits are restricted to a particular organ or tissue. Alzheimer’s, Parkinson’s disease, and amyotrophic lateral sclerosis are some examples of neurodegenerative amyloidosis. Local manifestation of protein aggregation in the skin has also been reported. Brain and skin are highly connected at a physiological and pathological level. Recently several studies demonstrated a strong connection between brain and skin in different amyloid diseases. In the present review, we discuss the relevance of the “brain–skin connection” in different neurodegenerative amyloidosis, not only at the pathological level, but also as a strategy for the treatment of these diseases

Topics: Neuroscience
Publisher: Frontiers Research Foundation
OAI identifier: oai:pubmedcentral.nih.gov:3262151
Provided by: PubMed Central

Suggested articles

Citations

  1. (2005). A peptide vaccine administeredtranscutaneouslytogetherwith choleratoxinelicitspotentneutralising anti-FMDV antibody responses.
  2. (1997). Aberrant retention of tyrosinase in the endoplasmic reticulum mediates accelerated degradation of the enzyme and contributes to the dedifferentiated phenotype of amelanotic melanoma cells.
  3. (2011). accepted: 04
  4. (1999). Alpha-synuclein fibrillogenesis is nucleation-dependent. Implications for the pathogenesis of Parkinson’s disease.
  5. (1997). Alphasynuclein in Lewy bodies.
  6. (1998). Alterations of skin glycosaminoglycans in patients withALS.
  7. (2002). Alzheimer’s disease: treatments in discovery and development.
  8. (1992). Amyloid beta-protein deposition in skin of patients with dementia.
  9. (1998). Amyloid fibril formation by anSH3domain.Proc.Natl.Acad.Sci.
  10. (2000). Amyloid fibrillogenesis: themes and variations.
  11. (2008). Amyloid toxicity is independent of polypeptide sequence,
  12. (1983). Amyloidogenesis in organlimited cutaneous amyloidosis: an antigenic identity between epidermal keratin and skin amyloid.
  13. (2009). amyloidogenesis:nucleation-dependentfibrillation versus double-concerted fibrillation.
  14. (1993). Amyotrophic lateral sclerosis and structural defects in Cu, Zn superoxide dismutase.
  15. (2008). Amyotrophic lateral sclerosis models and human neuropathology: similarities and differences.
  16. (2009). Amyotrophic lateral sclerosis, frontotemporal dementia and beyond: the TDP-43 diseases.
  17. (2001). Analysis of the minimal amyloidforming fragment of the islet amyloid polypeptide. An experimental support for the key role of the phenylalanine residue in amyloid formation.
  18. and Lemere,C.A.(2006).Shortamyloidbeta (Abeta) immunogens reduce cerebral Abeta load and learning deficits in an Alzheimer’s disease mouse model in the absence of an Abeta-specific cellular immune response.J.Neurosci.26,4717–4728.
  19. and Montgomery,G.W.(2010).Multiple pigmentation gene polymorphisms account for a substantial proportion of risk of cutaneous malignant melanoma.
  20. and Papadopoulos,V.(2009).Amyloidosis and neurodegenerative diseases: current treatments and new pharmacological options.
  21. (2001). Annual incidenceofAlzheimerdiseaseinthe United States projected to the years 2000 through 2050. Alzheimer Dis.
  22. (2008). ASIP and TYR pigmentation variants associate with cutaneous melanoma and basal cell carcinoma.
  23. (2000). Assembly of tau protein into Alzheimer paired helical filaments depends on a local sequence motif ((306)VQIVYK(311)) forming beta structure.
  24. (1999). associated with mutations in superoxide dismutase: a putative mechanism of degeneration. Brain Res. Brain Res.
  25. (1993). Beta-adrenergic receptors in psoriasis: evidence for downregulationinlesionalskin.Arch.Dermatol.
  26. (1993). Betaadrenergic blocking drugs and psoriasis: the role of an immunologic mechanism.
  27. (2010). Biology of amyloid: structure, function, and regulation.
  28. (2000). Blood oxidative stress and lipoprotein oxidizability in haemodialysis patients: effect of the use of a vitamin Ecoated dialysis membrane.
  29. C.(1996).Aplacebo-controlledtrial of recombinant human ciliary neurotrophic (rhCNTF) factor in amyotrophic lateral sclerosis.
  30. (2007). Caregiver preference for rivastigmine patch relative to capsules for treatment of probable Alzheimer’s disease.
  31. (2007). Caregiver preference for rivastigmine patches versus capsules for the treatment of Alzheimer disease.
  32. (2009). Characterization of PLA2G6 as a locus for dystonia-parkinsonism.
  33. (2004). Ciliary neurotrophic factor (CNTF) for amyotrophic lateral sclerosis/motor neuron disease. Cochrane Database Syst.
  34. (1986). Collagenase activityinskinfibroblastsofpatients with amyotrophic lateral sclerosis.
  35. (1979). Colloid-amyloid bodies in PUVA-treated human psoriatic patients.
  36. (2004). Colocalization of different types of amyloid in the walls of cerebral blood vessels of patients suffering from cerebral amyloid angiopathy www.frontiersin.org
  37. (1992). Colocalization of prion protein and beta protein in the same amyloid plaques in patients with Gerstmann-Straussler syndrome.
  38. (2006). Common mechanisms of amyloid oligomer pathogenesisindegenerativedisease.Neurobiol.
  39. (2006). Common structure and toxic function of amyloid oligomers implies a common mechanism of pathogenesis.Neurology 66(Suppl.1),S74–S78.
  40. (2009). Contribution of TARDBP mutations to sporadic amyotrophic lateral sclerosis.
  41. (2001). Copper neurotoxicity is dependent on dopaminemediated copper uptake and oneelectron reduction of aminochrome in a rat substantia nigra neuronal cell line.
  42. (2000). Corticotropin releasing hormone and proopiomelanocortin involvement in the cutaneous response to stress.
  43. (1994). Cu/Zn superoxide dismutase-like immunoreactivityinLewybody-like inclusions of sporadic amyotrophic lateral sclerosis.
  44. (2009). Currents concepts on the immunopathology of amyloidosis.
  45. (1991). Cytopathology of amyotrophic lateral sclerosis.
  46. (1991). Cytoskeletal pathology in motor neuron diseases.
  47. (1999). De novo amyloid proteins from designed combinatorial libraries.
  48. (2002). De novo designed peptidebased amyloid fibrils.
  49. (2002). Decreased cutaneous vasodilatation to isometric handgrip exercise in Alzheimer’s disease.
  50. (1998). Decreased type IV collagen of skin and serum in patients with amyotrophic lateral sclerosis.
  51. (1999). Designing conditions for in vitro formation of amyloid protofilaments and fibrils.
  52. (1984). Differential staining of cytoid bodies and skin-limited amyloids with monoclonal antikeratin antibodies.
  53. (2008). Disseminated nodular primary localized cutaneous amyloidosis.
  54. E.,andKelly,J.W.(2007).Functional amyloid – from bacteria to humans.
  55. (1997). Effect of recombinant human insulin-like growth factor-I on progression of ALS.
  56. (1999). Efficacy and safety of rivastigmine in patients with Alzheimer’s disease: international randomised controlled trial.
  57. (2010). Exploring the sequence determinants of amyloid structure using position-specific scoring matrices.
  58. (1994). Expression of amyloid beta-protein precursor mRNAs in cultured skin fibroblasts taken from patients with dementia of the Alzheimer type.
  59. (2003). Expressionof beta-amyloidandtauprotein in mastocytes in Alzheimer disease.
  60. (2009). Fibrils from designed non-amyloidrelated synthetic peptides induce AA-amyloidosis during inflammation in an animal model.
  61. (2009). Functional amyloids as natural storage of peptidehormonesinpituitarysecretory granules.
  62. G.A.(2006).Geneticsoffamilialand sporadic amyotrophic lateral sclerosis.
  63. (2009). Granular assembly of alpha-synuclein leading to the accelerated amyloid fibril formation with shear stress.
  64. (2009). Highly pathogenic H5N1 influenza virus can enter the central nervous system and induce neuroinflammation and neurodegeneration.Proc.Natl.Acad.
  65. (1980). Histogenesis of amyloid in the skin.
  66. (1982). Histogenesis of macular amyloidosis.
  67. (1979). Histogenesis of primary localized cutaneous amyloidosis: sequential change of epidermal keratinocytes to amyloid via filamentous degeneration.
  68. (2005). How best to fight that nasty itch – from new insights into the neuroimmunological, neuroendocrine, and neurophysiological bases of pruritus to novel therapeutic approaches.
  69. (2010). How much is dementia care worth?
  70. (2007). Impaired peripheral endothelial microvascular responsiveness in Alzheimer’s disease.
  71. (2007). In vitro polymerization of a functional Escherichia coli amyloid protein.
  72. (2000). Increased amyloid beta protein in the skin of patients with amyotrophic lateral sclerosis.
  73. (2010). Increased expression of TDP-43 in the skin of amyotrophic lateral sclerosis.
  74. (2004). Induction of AApoAII amyloidosis by various heterogeneous amyloid fibrils.
  75. (2003). Interactions of amyloidogenic proteins.
  76. (2006). Intranasal immunization with human papillomavirus type 16 capsomeres in the presence of non-toxic cholera toxin-based adjuvants elicits increased vaginal immunoglobulin levels.
  77. (1976). Letter: amyotrophic lateral sclerosis and bedsores.
  78. (2009). Linking neuron and skin: matrix metalloproteinases in amyotrophic lateral sclerosis (ALS).
  79. (2001). Loss of presenilin 1 is associated with enhanced beta-catenin signaling and skin tumorigenesis.
  80. M.,andStefani,M.(2004).Prefibrillar amyloid protein aggregates share common features of cytotoxicity.
  81. M.(2006).UbiquitinatedTDP-43in frontotemporal lobar degeneration and amyotrophic lateral sclerosis.
  82. (1971). Macular amyloidosis. A study of 21 cases with special reference to the role of the epidermis in its histogenesis.
  83. (2003). Mast cells, nerves and neuropeptides in atopic dermatitis and nummular eczema.
  84. (2010). MMP-2 and MMP-9 are elevated in spinal cord and skin in a mouse model of ALS.
  85. (1997). Models of amyloid seeding in Alzheimer’s disease and scrapie: mechanistictruthsandphysiological consequencesofthetime-dependent solubilityofamyloidproteins.Annu.
  86. (2005). Modulation of thehumoralandcellularimmune response in Abeta immunotherapy by the adjuvants monophosphoryl lipid A (MPL), cholera toxin B subunit (CTB) and E. coli enterotoxin LT(R192G).
  87. (2008). Molecular and cellular aspects of protein misfolding and disease.
  88. (1993). Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis.
  89. (2008). Natural protective amyloids.
  90. (2004). Neurogenic inflammation in stress-induced termination of murine hair growth is promoted bynervegrowthfactor .Am.J.Pathol.
  91. (2009). Neuropathology of non-motor features of Parkinson disease. Parkinsonism Relat.
  92. (1992). Nomenclature and classificationofamyloidandamyloidoses.
  93. (2009). Non-motor extranigral signs and symptoms in Parkinson’s disease.
  94. (2002). Oxidativestressandreducedantioxidant defenses in peripheral cells from familial Alzheimer’s patients.
  95. (2004). Parkinson’s disease.
  96. (2004). Partial loss of presenilins causes seborrheic keratosis and autoimmune disease in mice.
  97. (1998). placebo-controlled trial of insulin-like growth factor-I in amyotrophic lateral sclerosis.
  98. (2008). Polymerizing the fibre between bacteria and host cells: the biogenesis of functional amyloid fibres.
  99. (2010). Preparation and characterization of neurotoxic tau oligomers.
  100. (1994). Presence of non-fibrillar amyloid beta protein in skin biopsies of Alzheimer’s disease (AD), Down’s syndrome and non-AD normal persons.ActaNeuropathol.88,201–206.
  101. (2007). Presenilin 1 regulates epidermal growth factor receptor turnover and signaling in the endosomal-lysosomal pathway.
  102. (2009). Primary cutaneousnodularamyloidosis:case report and review of the literature.
  103. (2003). Protein aggregation and aggregate toxicity: new insights into protein folding,misfoldingdiseasesandbiological evolution.
  104. (2008). Protein folding and cutaneous diseases.
  105. (2006). Protein misfolding, functional amyloid, and human disease.
  106. (2005). Psychological factors in psoriasis: consequences,mechanisms,and interventions.
  107. (2007). Recombinant human insulin-like growth factor I (rhIGFI) for amyotrophic lateral sclerosis/motor neuron disease. Cochrane Database Syst.
  108. (2007). Rivastigmine exposure provided by a transdermal patch versus capsules.
  109. Rocken,C.,Schwotzer,E.B.,Linke,R.P., andSaeger,W.(1996).Theclassification of amyloid deposits in clinicopathological practice.
  110. (2000). Role of nerve growth factor in RANTES expression by keratinocytes.
  111. (2011). Role of oligomers
  112. Rouleau,G. A.(2009).Geneticsof motorneuron disorders: new insights into pathogenic mechanisms.
  113. (2008). Secondary cutaneous nodular AA amyloidosis in a patient withprimarySjogrensyndromeand celiac disease.
  114. (1993). Seeding “one-dimensional crystallization” of amyloid: a pathogenic mechanism in Alzheimer’s disease and scrapie?
  115. (2007). Signal transduction and cell-type specific regulation of matrix metalloproteinase gene expression: can MMPs be good for you?
  116. (2012). Skin and treatment of neurodegenerative amyloidosis
  117. (2012). Skin and treatment of neurodegenerative amyloidosis Meersman,F.,Dobson,C.M.,andHeremans,
  118. (1996). Sporadic amyotrophic lateral sclerosis with dementia and Cu/Zn superoxide dismutasepositive Lewy body-like inclusions.
  119. (2003). Staging of brain pathology related to sporadic Parkinson’sdisease.Neurobiol.Aging
  120. (2005). Stress and psychoneuroimmunologic factors in dermatology.
  121. (2003). Stress inhibits hair growth in mice by induction of premature catagen development and deleterious perifollicular inflammatory events via neuropeptide substance P-dependent pathways.
  122. (2005). Structure of the cross-beta spine of amyloidlike fibrils.
  123. (2002). Superoxide dismutase multigene family: a comparison of the CuZn-SOD (SOD1), Mn-SOD (SOD2), and EC-SOD (SOD3) gene structures, evolution, and expression. Free Radic.
  124. (2008). TDP-43 A315T mutation in familial motor neuron disease.
  125. (2006). TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis.
  126. (2008). TDP-43 mutations in familial and sporadic amyotrophiclateralsclerosis.Science 319,
  127. (1970). The cutaneous amyloidosis. I. Localized forms.
  128. (2006). The matrix metalloproteinases inhibitor Ro 28-2653 [correction of Ro 26-2853] extends survival in transgenic ALSmice.Exp.Neurol.200,166–171.
  129. (1971). The role of the epidermis in the histopathogenesis of lichen amyloidosis. Histochemical correlations.
  130. (2010). Therapeutic removal of amyloid deposits in cutaneous amyloidosis by localised intra-lesional injections of antiamyloid antibodies.
  131. (2007). Transcutaneous beta-amyloid immunization reduces cerebral betaamyloid deposits without T cell infiltration and microhemorrhage.
  132. (2005). Transcutaneous immunization with cytotoxic T-cell peptide epitopes provides effective antitumor immunity inmice.J.Immunother.28,430–437.
  133. (2006). Transdermal delivery of drugsforurologicapplications:basic principles and applications.
  134. (2007). Ubiquitinated pathological lesions in frontotemporal lobar degeneration contain the TAR DNA-binding protein,TDP-43.ActaNeuropathol.113,
  135. (1996). Ultrastructural evidence for colocalization of kappa light chainand beta 2-microglobulin-derived amyloids using double labelling immunogold electron microscopy. Virchows Arch.
  136. (2010). Yeast cell adhesion molecules have functional amyloidforming sequences.

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.